GLICLAZIDE MR VIATRIS gliclazide 30 mg modified release tablet bottle

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

gliclazide, Quantity: 30 mg

Pieejams no:

Alphapharm Pty Ltd

Zāļu forma:

Tablet, modified release

Kompozīcija:

Excipient Ingredients: magnesium stearate; microcrystalline cellulose; hypromellose

Ievadīšanas:

Oral

Vienības iepakojumā:

100

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

Type II diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,During controlled clinical trials in patients with type II diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of HbA1c.

Produktu pārskats:

Visual Identification: A white to off-white, oblong, biconvex tablet debossed with M on one side of the tablet and GL 30 on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Autorizācija statuss:

Registered

Autorizācija datums:

2023-03-31